2. St. Elisabeth Hospital, Tilburg, The Netherlands
Global Analysis of SARS-CoV-2 Serology, Part 2
The outbreak of SARS-CoV-2 in late 2019 caused a pandemic, currently in its fourth wave, with a huge medical, societal, and economic impact. Based on detailed knowledge of the viral genome and the major proteins of the virus, molecular and serological assays have been rapidly developed. A wide range of serological assays (both in-house as well as commercial) for SARS-CoV-2 have been validated and implemented. These have been instrumental for diagnostics and for monitoring of the course and severity of COVID-19. For now and in the future, (functional) serological assays will (also) be important for monitoring vaccine coverage against emerging variants of SARS-CoV-2, including the Omicron variant and subvariants. The global aspect and impact of SARS-CoV-2 serology is illustrated through the emergence of variant strains in different parts of the world. In this Special Issue, we aim to bring together views from clinical and basic specialists around the world on the pathogen, its biology, and the vaccines (monovalent and multivalent adapted to omicron variants and others). We welcome your submissions.
Prof. Dr. Ger Rijkers
Dr. Jean-Luc Murk
- virus neutralization
- antibody affinity
- variant strains
|Journal Name||Impact Factor||CiteScore||Launched Year||First Decision (median)||APC|
|-||-||2021||15.0 days *||1000 CHF||Submit|
|5.168||2.8||2012||16.1 Days||2200 CHF||Submit|
Methods and Protocolsmps
|-||3.0||2018||26.3 Days||1600 CHF||Submit|
|4.531||3.5||2012||15.9 Days||2200 CHF||Submit|
|4.961||4.5||2013||17.3 Days||2200 CHF||Submit|
* Median value for all MDPI journals in the second half of 2022.
Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.